The inhaled nitric oxide (iNO) therapy shall reduce the clinical necessity of a left-to-right shunt and contribute to cardiac relief. In order to improve the oxygenation of ventilated patients’ nitric oxide (NO) is added to the respiratory gas.
It is applied for the treatment of newborns, children and adults with pulmonary hypertension, oxygen deficiency, neonatal pulmonary failure, persistent pulmonary hypertension of neonates, pulmonary fibrosis, chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS). Furthermore, the device is used in cardiac surgery (cardiac valve diseases and cardiac transplantation) to treat an increased pulmonary pressure, as inhaled NO has a dilating effect on the blood vessels in the lung and therefore significantly improves the haemodynamics of the patient.
